Johnson & Johnson $JNJ Shares Purchased by Motco

Motco boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 72,301 shares of the company’s stock after acquiring an additional 337 shares during the quarter. Johnson & Johnson makes up 1.1% of Motco’s investment portfolio, making the stock its 28th biggest position. Motco’s holdings in Johnson & Johnson were worth $11,911,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. GFG Capital LLC purchased a new position in Johnson & Johnson during the second quarter worth about $35,000. Stone House Investment Management LLC purchased a new position in Johnson & Johnson during the first quarter worth about $47,000. 1248 Management LLC purchased a new position in Johnson & Johnson during the first quarter worth about $48,000. von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in shares of Johnson & Johnson in the first quarter valued at approximately $52,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Down 1.8%

Shares of NYSE:JNJ opened at $186.94 on Wednesday. The firm’s 50 day moving average price is $182.72 and its 200 day moving average price is $166.92. The stock has a market cap of $450.40 billion, a price-to-earnings ratio of 18.04, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm’s stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.16% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. JPMorgan Chase & Co. raised their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a research note on Tuesday, September 16th. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the company from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Weiss Ratings raised shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Finally, Cowen reissued a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.